Fig. 10From: Construction of a nine DNA repair-related gene prognostic classifier to predict prognosis in patients with endometrial carcinomaDifferential putative chemotherapeutic and immunotherapeutic response of the high- and low-risk groups. The box plots of the estimated IC50 for cisplatin, paclitaxel, bleomycin, vinblastine, gemcitabine, rapamycin, metformin, imatinib, Akt inhibitor and lapatinibBack to article page